Immunohistochemistry (IHC) biomarkers are key components of today’s drug and companion diagnostic programs to identify and validate potential drug targets, stratify patient populations, and monitor treatment response. Our team of biomarker experts can assist you in identifying and understanding relevant biomarkers in your target populations, allowing you to make informed decisions with speed and confidence. We offer IHC assay development, validation, and implementation services to generate high-quality, reliable data for all phases of drug or diagnostic development.